Patrick Mutombo Lupola

Mr. Patrick Mutombo Lupola

National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
LPLaurene Peckeu-Abboud
Laurene Peckeu-Abboud
PMPatrick Mangoni
Patrick Mangoni
KCKaouther Chammam
Kaouther Chammam
PKPapy Kwete
Papy Kwete
PLPatrick Mutombo Lupola
Patrick Mutombo Lupola
PMPlacide Mbala
Placide Mbala
We performed a cross-sectional survey on vaccination-related knowledge, attitudes, and practices (KAP) among randomly selected parents of <5 years-old children, elderly populations (aged ≥ 55 years), and health care workers (HCWs) in 10 health zones from 4 provinces of the Democratic Republic of Congo (DRC). Questionnaires targeted both routine (BCG, measles, polio) and outbreak-related (cholera, Ebola, COVID-19) vaccinations. In total, 2751 participants were included, 1165 parents, 1040 elderly, and 546 HCWs. In general, KAP expressed were supportive of vaccination uptake, although concerns regarding side effects and feelings of being insufficiently informed were more prevalent among parents and the elderly. Vaccine acceptance was lower for outbreak vaccinations (57%) than for routine vaccinations (90%). HCWs expressed the highest vaccine acceptance. Problems with the vaccine supply chain were reported by 20% of respondents. Despite a high level of positive KAP towards vaccination, parents and the elderly expressed a need to be better informed and had concerns regarding vaccine side-effects. A high acceptance for routine vaccinations was reported by participants, but somewhat less for outbreak vaccinations. In conclusion, HCWs in the communities could play a key role in the increased uptake of routine vaccinations and in optimizing uptake during outbreaks, provided that the supply chain is functioning well.

6 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CKCécile Kremer
Cécile Kremer
SNSabin Sabiti Nundu
Sabin Sabiti Nundu
EVEmmanuel Hasivirwe Vakaniaki
Emmanuel Hasivirwe Vakaniaki
IBIsabel Brosius
Isabel Brosius
GMGuy Mukari
Guy Mukari
ATAndrea Torneri
Andrea Torneri
Monkeypox virus (MPXV) Clade Ib, a new MPXV subclade associated with sustained human-to-human transmission, emerged in eastern DRC in late 2023. Early spread mainly occurred among the adult population, primarily through sexual contact. We investigate how key epidemiological characteristics of the new MPXV Clade Ib outbreak in the DRC differ by transmission mode. We estimate the mean serial interval to be 8.57 days (95% CI 7.15 − 9.91 days). The serial interval is approximately four days shorter for putative sexual compared to non-sexual transmission. We estimate the mean incubation period to be 9.56 days (95% CrI 8.22 − 11.02 days), and approximately two days shorter for putative sexual compared to non-sexual transmission. These observed differences in serial interval and incubation period estimates by transmission mode suggest that the context in which an outbreak occurs is an essential factor to consider when devising public health policies.

1 June 2024 in Journal of Health, Population and Nutrition
Verified
Journal Article
Open access
PDF file
JMJoule Madinga
Joule Madinga
PMPlacide Kingebeni Mbala
Placide Kingebeni Mbala
Antoine Nkuba-NdayeAntoine Nkuba-Ndaye
Antoine Nkuba-Ndaye
LBLeonel Baketana-Kinzonzi
Leonel Baketana-Kinzonzi
PLPatrick Mutombo Lupola
Patrick Mutombo Lupola
VVVeerle Vanlerberghe
Veerle Vanlerberghe
Introduction: Serological surveys offer the most direct measurement to define the immunity status for numerous infectious diseases, such as COVID-19, and can provide valuable insights into understanding transmission patterns. This study describes seroprevalence changes over time in the context of the Democratic Republic of Congo, where COVID-19 case presentation was apparently largely oligo- or asymptomatic, and vaccination coverage remained extremely low. Methods: A cohort of 635 health care workers (HCW) from 5 health zones of Kinshasa and 670 of their household members was interviewed and sampled in 6 rounds between July 2020 and January 2022. At each round, information on risk exposure and a blood sample were collected. Serology was defined as positive when binding antibodies against SARS-CoV-2 spike and nucleocapsid proteins were simultaneously present. Results: The SARS-CoV-2 antibody seroprevalence was high at baseline, 17.3% (95% CI 14.4–20.6) and 7.8% (95% CI 5.5–10.8) for HCW and household members, respectively, and fluctuated over time, between 9% and 62.1%. Seropositivity was heterogeneously distributed over the health zones (p < 0.001), ranging from 12.5% (95% CI 6.6–20.8) in N’djili to 33.7% (95% CI 24.6–43.8) in Bandalungwa at baseline for HCW. Seropositivity was associated with increasing rounds adjusted Odds Ratio (aOR) 1.75 (95% CI 1.66–1.85), with increasing age aOR 1.11 (95% CI 1.02–1.20), being a female aOR 1.35 (95% CI 1.10–1.66) and being a HCW aOR 2.38 (95% CI 1.80–3.14). There was no evidence that HCW brought the COVID-19 infection back home, with an aOR of 0.64 (95% CI 0.46–0.91) of seropositivity risk among household members in subsequent surveys. There was seroreversion and seroconversion over time, and HCW had a lower risk of seroreverting than household members (aOR 0.60 (95% CI 0.42–0.86)). Conclusion: SARS-CoV-2 IgG antibody levels were high and dynamic over time in this African setting with low clinical case rates. The absence of association with health profession or general risk behaviors and with HCW positivity in subsequent rounds in HH members, shows the importance of the time-dependent, and not work-related, force of infection. Cohort seroprevalence estimates in a ‘new disease’ epidemic seem insufficient to guide policy makers for defining control strategies.

11 July 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
LOLeader Lawanga Ontshick
Leader Lawanga Ontshick
JYJepsy Grace Yango wa yango
Jepsy Grace Yango wa yango
AYAnge Mubiala Yaya
Ange Mubiala Yaya
OMOlivier Tshiani Mbaya
Olivier Tshiani Mbaya
JTJoule Madinga Twan
Joule Madinga Twan
RMRostin Mabela Makengo Matendo
Rostin Mabela Makengo Matendo
Ebola Virus Disease (EVD) remains a significant public health threat, particularly in sub-Saharan Africa. During the 10th Ebola outbreak in the Democratic Republic of Congo (DRC), the Pamoja Tulinde Maisha clinical trial (PALM-RCT) provided a unique opportunity to evaluate new therapeutic interventions. Despite these advances, limited knowledge exists regarding the dynamic evolution of mortality risk factors in EVD patients. This study aimed to model risk factors associated with mortality using logistic regression on unbalanced panel data from patients enrolled in this trial.We conducted a retrospective secondary analysis of longitudinal data from 617 EVD patients included in the PALM-RCT. Data were collected at five time points: Day0 (admission), Day7, Day14, Day21, and Day28. A binary logistic regression model was applied at each time point to identify significant predictors of mortality. The Hosmer-Lemeshow test was used to assess model calibration and internal validation. At Day0 (admission), six significant predictors of mortality were identified: viral load (RT-PCR cycle threshold value), creatinine, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), haemorrhage, shortness of breath, and conjunctivitis. By Day7, five predictors emerged: sodium, ASAT, coma, abdominal pain, and shortness of breath. At Day14, two predictors remained significant: ASAT and mental state changes. No significant predictors were identified at Day21 and Day28. The dynamic nature of these risk factors highlights the importance of continuous monitoring throughout the clinical course of EVD.Our study demonstrates that mortality risk factors in EVD patients evolve over time, suggesting that a dynamic approach to patient monitoring is critical. Early risk factors such as viral load and renal function should guide initial interventions, while neurological symptoms and electrolyte imbalances require attention in later stages. These findings support a personalized approach to EVD management, where clinical care is adjusted based on real-time clinical data to improve patient outcomes.